TITLE

奈达铂联合5 氟尿嘧啶对晚期食管癌患者CEA及SCC 水平的影响及其 临床疗效

AUTHOR(S)
吕红博; 瓦热斯江·衣不拉音; 罗洞波; 阿迪力·萨来; 孙晓宏
PUB. DATE
June 2016
SOURCE
Progress in Modern Biomedicine;Jun2016, Vol. 16 Issue 18, p3489
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: To investigate the effect of nedaplatin combined with 5 fluorouracil on the changes of CEA and SCC and its clinical efficacy for patients with advanced esophageal cancer. Methods: 60 patients with advanced esophageal cancer who were treated in our hospital were selected and randomly divided into the experiment group and the control group, with 30 cases in each group. The patients in the control group were treated with cisplatin 5-fluorouracil chemotherapy, while the patients in the experiment group were treated with the nedaplatin 5-fluorouracil(5-FU) chemotherapy. Then the changes of CEA and SCC, and the treatment toxic reaction rate and clinical efficacy were observed and compared before and after the treatment. Results: Compared with before treatment, the levels of CEA and SCC in the two groups decreased after the treatment, and the differences were statistically significant(P<0.05); Compared with the control group, the levels of CEA and SCC in the experiment group were lower than those of the control group, and the differences were statistically significant(P<0.05); The toxic reaction rate in the experiment group was lower than that of the control group, and the difference was statistically significant(P<0.05); The clinical efficacy in the experiment group was higher than that of the control group,and the difference was statistically significant(P<0.05). Conclusion: Nedaplatin combined with 5-fluorouracil can reduce the levels of CEA and SCC and the toxic reactions of patients with esophageal cancer, and improve the clinical efficacy.
ACCESSION #
118031467

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics